Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Liver Diseases

  Free Subscription

Articles published in J Gastroenterol

Retrieve available abstracts of 50 articles:
HTML format

Single Articles

    May 2022
  1. AMPUERO J, Gallego-Duran R, Maya-Miles D, Montero R, et al
    Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.
    J Gastroenterol. 2022;57:357-371.
    PubMed     Abstract available

    April 2022
  2. NISHIDA N, Yamakawa M, Shiina T, Mekada Y, et al
    Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts.
    J Gastroenterol. 2022;57:309-321.
    PubMed     Abstract available

  3. IRITANI S, Kawamura Y, Muraishi N, Fujiyama S, et al
    The useful predictors of zinc deficiency for the management of chronic liver disease.
    J Gastroenterol. 2022;57:322-332.
    PubMed     Abstract available

    March 2022
  4. SUZUKI Y, Mori T, Momose H, Matsuki R, et al
    Predictive factors for subsequent intrahepatic cholangiocarcinoma associated with hepatolithiasis: Japanese National Cohort Study for 18 years.
    J Gastroenterol. 2022 Mar 31. pii: 10.1007/s00535-022-01868.
    PubMed     Abstract available

  5. LIN W, Lin J, Li J, Lin Y, et al
    Kindlin-2-miR-1258-TCF4 feedback loop promotes hepatocellular carcinoma invasion and metastasis.
    J Gastroenterol. 2022 Mar 4. pii: 10.1007/s00535-022-01866.
    PubMed     Abstract available

    February 2022
  6. WANG XH, Hu ZL, Fu YZ, Hou JY, et al
    Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
    J Gastroenterol. 2022 Feb 13. pii: 10.1007/s00535-022-01855.
    PubMed     Abstract available

    January 2022
  7. SAKAMORI R, Yamada R, Tahata Y, Kodama T, et al
    The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery.
    J Gastroenterol. 2022 Jan 22. pii: 10.1007/s00535-021-01842.
    PubMed     Abstract available

  8. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
    J Gastroenterol. 2022 Jan 20. pii: 10.1007/s00535-021-01845.
    PubMed     Abstract available

  9. SEKO Y, Moriguchi M, Takahashi A, Yamaguchi K, et al
    Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.
    J Gastroenterol. 2022 Jan 15. pii: 10.1007/s00535-021-01837.
    PubMed     Abstract available

    December 2021
  10. BURGHART L, Halilbasic E, Schwabl P, Simbrunner B, et al
    Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis.
    J Gastroenterol. 2021 Dec 11. pii: 10.1007/s00535-021-01839.
    PubMed     Abstract available

  11. NAKAYAMA N, Uemura H, Uchida Y, Imai Y, et al
    Nationwide survey for patients with acute-on-chronic liver failure occurring between 2017 and 2019 and diagnosed according to proposed Japanese criteria.
    J Gastroenterol. 2021;56:1092-1106.
    PubMed     Abstract available

  12. KAMADA Y, Takahashi H, Shimizu M, Kawaguchi T, et al
    Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review.
    J Gastroenterol. 2021;56:1045-1061.
    PubMed     Abstract available

    November 2021
  13. MATSUMOTO K, Ohfuji S, Abe M, Komori A, et al
    Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study.
    J Gastroenterol. 2021 Nov 18. pii: 10.1007/s00535-021-01836.
    PubMed     Abstract available

  14. YONEDA M, Yamamoto T, Honda Y, Imajo K, et al
    Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    J Gastroenterol. 2021;56:1022-1032.
    PubMed     Abstract available

    September 2021
  15. HANAI T, Nishimura K, Miwa T, Maeda T, et al
    Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020.
    J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01821.
    PubMed     Abstract available

  16. TOKUSHIGE K, Ikejima K, Ono M, Eguchi Y, et al
    Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
    J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01796.
    PubMed     Abstract available

    July 2021
  17. LI D, Ding X, Tian D, Xia L, et al
    Reply to: "COVID-19-associated liver injury (COVALI): role of hepatologists".
    J Gastroenterol. 2021 Jul 12. pii: 10.1007/s00535-021-01807.

  18. YOSHIJI H, Nagoshi S, Akahane T, Asaoka Y, et al
    Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
    J Gastroenterol. 2021 Jul 7. pii: 10.1007/s00535-021-01788.
    PubMed     Abstract available

  19. SUMIDA Y, Yoneda M
    COVID-19-associated liver injury (COVALI): role of hepatologists.
    J Gastroenterol. 2021 Jul 2. pii: 10.1007/s00535-021-01809.

    May 2021
  20. OKUSAKA T, Ikeda K, Kudo M, Finn R, et al
    Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
    J Gastroenterol. 2021 May 4. pii: 10.1007/s00535-021-01785.
    PubMed     Abstract available

    March 2021
  21. MAK LY, Huang Q, Wong DK, Stamm L, et al
    Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy.
    J Gastroenterol. 2021 Mar 27. pii: 10.1007/s00535-021-01780.
    PubMed     Abstract available

  22. NAKATSUKA T, Nakagawa H, Hayata Y, Wake T, et al
    Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma.
    J Gastroenterol. 2021 Mar 12. pii: 10.1007/s00535-021-01773.
    PubMed     Abstract available

  23. HUO TI, Ho SY, Liu PH
    Changing patterns of etiology and management of hepatocellular carcinoma: need for global reappraisal.
    J Gastroenterol. 2021 Mar 11. pii: 10.1007/s00535-021-01770.

  24. ENOMOTO H, Nishiguchi S
    Reply to the letter by Huo et al. regarding our manuscript "The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan".
    J Gastroenterol. 2021 Mar 11. pii: 10.1007/s00535-021-01768.

  25. LI D, Ding X, Xie M, Tian D, et al
    COVID-19-associated liver injury: from bedside to bench.
    J Gastroenterol. 2021;56:218-230.
    PubMed     Abstract available

    February 2021
  26. ISHIKAWA T, Sasaki R, Nishimura T, Matsuda T, et al
    Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism.
    J Gastroenterol. 2021 Feb 24. pii: 10.1007/s00535-021-01762.
    PubMed     Abstract available

    January 2021
  27. TERAI S, Buchanan-Hughes A, Ng A, Lee IH, et al
    Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
    J Gastroenterol. 2021 Jan 26. pii: 10.1007/s00535-021-01759.
    PubMed     Abstract available

  28. TATEISHI R, Matsumura T, Okanoue T, Shima T, et al
    Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan.
    J Gastroenterol. 2021 Jan 11. pii: 10.1007/s00535-020-01754.
    PubMed     Abstract available

  29. KUDO M, Tsuchiya K, Kato N, Hagihara A, et al
    Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study.
    J Gastroenterol. 2021 Jan 3. pii: 10.1007/s00535-020-01753.
    PubMed     Abstract available

  30. HARADA M
    Diagnosis for Wilson disease: this disease may not be a rare disease.
    J Gastroenterol. 2021;56:114-115.

  31. GARCIA-VILLARREAL L, Hernandez-Ortega A, Sanchez-Monteagudo A, Pena-Quintana L, et al
    Wilson disease: revision of diagnostic criteria in a clinical series with great genetic homogeneity.
    J Gastroenterol. 2021;56:78-89.
    PubMed     Abstract available

  32. JIANG L, Starkel P, Fan JG, Fouts DE, et al
    The gut mycobiome: a novel player in chronic liver diseases.
    J Gastroenterol. 2021;56:1-11.
    PubMed     Abstract available

    December 2020
  33. OCHI H, Hiraoka A, Hirooka M, Koizumi Y, et al
    Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.
    J Gastroenterol. 2020 Dec 5. pii: 10.1007/s00535-020-01747.
    PubMed     Abstract available

    November 2020
  34. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.
    J Gastroenterol. 2020 Nov 20. pii: 10.1007/s00535-020-01748.
    PubMed     Abstract available

  35. SUZUKI K, Suda G, Yamamoto Y, Furuya K, et al
    Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
    J Gastroenterol. 2020 Nov 19. pii: 10.1007/s00535-020-01750.
    PubMed     Abstract available

    October 2020
  36. YU WL, Yu G, Dong H, Chen K, et al
    Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2020 Oct 21. pii: 10.1007/s00535-020-01729.
    PubMed     Abstract available

  37. MIKI D, Akita T, Kurisu A, Kawaoka T, et al
    PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.
    J Gastroenterol. 2020 Oct 15. pii: 10.1007/s00535-020-01731.
    PubMed     Abstract available

  38. TAHATA Y, Hikita H, Mochida S, Kawada N, et al
    Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
    J Gastroenterol. 2020 Oct 1. pii: 10.1007/s00535-020-01733.
    PubMed     Abstract available

    September 2020
  39. YIP TC, Lai JC, Wong GL
    Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
    J Gastroenterol. 2020 Sep 24. pii: 10.1007/s00535-020-01726.
    PubMed     Abstract available

  40. HIRAMINE Y, Uto H, Mawatari S, Kanmura S, et al
    Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.
    J Gastroenterol. 2020 Sep 21. pii: 10.1007/s00535-020-01727.
    PubMed     Abstract available

    August 2020
  41. UCHIDA Y, Uemura H, Yamaba S, Hamada D, et al
    Significance of liver dysfunction associated with decreased hepatic CT attenuation values in Japanese patients with severe COVID-19.
    J Gastroenterol. 2020 Aug 9. pii: 10.1007/s00535-020-01717.
    PubMed     Abstract available

  42. ALI AH, Bi Y, Machicado JD, Garg S, et al
    The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience.
    J Gastroenterol. 2020 Aug 8. pii: 10.1007/s00535-020-01714.
    PubMed     Abstract available

  43. MARASCO G, Serenari M, Renzulli M, Alemanni LV, et al
    Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments.
    J Gastroenterol. 2020 Aug 3. pii: 10.1007/s00535-020-01711.
    PubMed     Abstract available

    July 2020
  44. TANAKA H, Okamoto K, Sato Y, Tanaka T, et al
    Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma.
    J Gastroenterol. 2020 Jul 14. pii: 10.1007/s00535-020-01705.
    PubMed     Abstract available

    June 2020
  45. LIANG LY, Wong VW, Toyoda H, Tse YK, et al
    Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients.
    J Gastroenterol. 2020 Jun 17. pii: 10.1007/s00535-020-01700.
    PubMed     Abstract available

  46. SAWADA Y, Shiraki M, Iwasa M, Hiraoka A, et al
    The effects of diuretic use and the presence of ascites on muscle cramps in patients with cirrhosis: a nationwide study.
    J Gastroenterol. 2020 Jun 12. pii: 10.1007/s00535-020-01694.
    PubMed     Abstract available

    May 2020
  47. SAKAIDA I, Terai S, Kurosaki M, Okada M, et al
    Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
    J Gastroenterol. 2020 May 9. pii: 10.1007/s00535-020-01691.
    PubMed     Abstract available

    March 2020
  48. KAWAGUCHI T, Torimura T
    Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients?
    J Gastroenterol. 2020;55:363-364.

    December 2019
  49. SCHWARZER R, Reiberger T, Mandorfer M, Kivaranovic D, et al
    The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.
    J Gastroenterol. 2019 Dec 12. pii: 10.1007/s00535-019-01656.
    PubMed     Abstract available

    May 2019
  50. NAGANUMA M, Sugimoto S, Suzuki H, Matsuno Y, et al
    Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey.
    J Gastroenterol. 2019 May 17. pii: 10.1007/s00535-019-01591.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.